Attached files
| file | filename |
|---|---|
| S-1 - S-1 - Eloxx Pharmaceuticals, Inc. | v421849_s1.htm |
| EX-5.1 - EXHIBIT 5.1 - Eloxx Pharmaceuticals, Inc. | v421849_ex5-1.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the use in this Registration Statement on Form S-1 of Sevion Therapeutics, Inc. and Subsidiaries of our report dated
October 8, 2015, relating to our audits of the financial statements appearing in the Prospectus, which is part of this Registration
Statement. Our report dated October 8, 2015, relating to the consolidated financial statements includes an explanatory paragraph
relating to an uncertainty as to the Company's ability to continue as a going concern.
We also consent to the reference to our firm under the caption "Experts" in this Prospectus.
/s/ McGladrey LLP
New York, New York
October 9, 2015